Müller-Wieland, D., Leiter, L. A., Cariou, B., Letierce, A., Colhoun, H. M., Del Prato, S., . . . Bujas-Bobanovic, M. (2017). Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: Lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovasc Diabetol.
Chicago Style CitationMüller-Wieland, Dirk, et al. "Design and Rationale of the ODYSSEY DM-DYSLIPIDEMIA Trial: Lipid-lowering Efficacy and Safety of Alirocumab in Individuals With Type 2 Diabetes and Mixed Dyslipidaemia At High Cardiovascular Risk." Cardiovasc Diabetol 2017.
Cita MLAMüller-Wieland, Dirk, et al. "Design and Rationale of the ODYSSEY DM-DYSLIPIDEMIA Trial: Lipid-lowering Efficacy and Safety of Alirocumab in Individuals With Type 2 Diabetes and Mixed Dyslipidaemia At High Cardiovascular Risk." Cardiovasc Diabetol 2017.